The global market for Infectious Vaccines was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

A vaccine is a medical product primarily designed to stimulate antibodies against an infectious disease which help to improve the immunity of the target body.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Infectious Vaccines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Infectious Vaccines.

The Infectious Vaccines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Infectious Vaccines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Infectious Vaccines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Infectious Vaccines Market Report

Report Metric	Details
Report Name	Infectious Vaccines Market
CAGR	5%
Segment by Type	Preventive Vaccine Therapeutic Vaccine
Segment by Application	Adults Pediatrics
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (U.K.), Emergent Bio Solutions Inc. (U.S.), MedImmune LLC (U.S.), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Sanofi Pasteur (France), Pfizer Inc. (U.S.)
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Infectious Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Infectious Vaccines Market report?

Ans: The main players in the Infectious Vaccines Market are CSL Limited (Australia), Bavarian Nordic (Denmark), GlaxoSmithKline plc. (U.K.), Emergent Bio Solutions Inc. (U.S.), MedImmune LLC (U.S.), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Sanofi Pasteur (France), Pfizer Inc. (U.S.)

What are the Application segmentation covered in the Infectious Vaccines Market report?

Ans: The Applications covered in the Infectious Vaccines Market report are Adults, Pediatrics

What are the Type segmentation covered in the Infectious Vaccines Market report?

Ans: The Types covered in the Infectious Vaccines Market report are Preventive Vaccine, Therapeutic Vaccine

1 Infectious Vaccines Market Overview

1.1 Product Definition

1.2 Infectious Vaccines by Type

1.2.1 Global Infectious Vaccines Market Value Comparison by Type (2024 VS 2031)

1.2.2 Preventive Vaccine

1.2.3 Therapeutic Vaccine

1.3 Infectious Vaccines by Application

1.3.1 Global Infectious Vaccines Market Value by Application (2024 VS 2031)

1.3.2 Adults

1.3.3 Pediatrics

1.4 Global Infectious Vaccines Market Size Estimates and Forecasts

1.4.1 Global Infectious Vaccines Revenue 2020-2031

1.4.2 Global Infectious Vaccines Sales 2020-2031

1.4.3 Global Infectious Vaccines Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Infectious Vaccines Market Competition by Manufacturers

2.1 Global Infectious Vaccines Sales Market Share by Manufacturers (2020-2025)

2.2 Global Infectious Vaccines Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Infectious Vaccines Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Infectious Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Infectious Vaccines, Product Type & Application

2.7 Global Key Manufacturers of Infectious Vaccines, Date of Enter into This Industry

2.8 Global Infectious Vaccines Market Competitive Situation and Trends

2.8.1 Global Infectious Vaccines Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Infectious Vaccines Players Market Share by Revenue

2.8.3 Global Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Infectious Vaccines Market Scenario by Region

3.1 Global Infectious Vaccines Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Infectious Vaccines Sales by Region: 2020-2031

3.2.1 Global Infectious Vaccines Sales by Region: 2020-2025

3.2.2 Global Infectious Vaccines Sales by Region: 2026-2031

3.3 Global Infectious Vaccines Revenue by Region: 2020-2031

3.3.1 Global Infectious Vaccines Revenue by Region: 2020-2025

3.3.2 Global Infectious Vaccines Revenue by Region: 2026-2031

3.4 North America Infectious Vaccines Market Facts & Figures by Country

3.4.1 North America Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Infectious Vaccines Sales by Country (2020-2031)

3.4.3 North America Infectious Vaccines Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Infectious Vaccines Market Facts & Figures by Country

3.5.1 Europe Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Infectious Vaccines Sales by Country (2020-2031)

3.5.3 Europe Infectious Vaccines Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Infectious Vaccines Market Facts & Figures by Region

3.6.1 Asia Pacific Infectious Vaccines Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Infectious Vaccines Sales by Region (2020-2031)

3.6.3 Asia Pacific Infectious Vaccines Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Infectious Vaccines Market Facts & Figures by Country

3.7.1 Latin America Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Infectious Vaccines Sales by Country (2020-2031)

3.7.3 Latin America Infectious Vaccines Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Infectious Vaccines Market Facts & Figures by Country

3.8.1 Middle East and Africa Infectious Vaccines Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Infectious Vaccines Sales by Country (2020-2031)

3.8.3 Middle East and Africa Infectious Vaccines Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Infectious Vaccines Sales by Type (2020-2031)

4.1.1 Global Infectious Vaccines Sales by Type (2020-2025)

4.1.2 Global Infectious Vaccines Sales by Type (2026-2031)

4.1.3 Global Infectious Vaccines Sales Market Share by Type (2020-2031)

4.2 Global Infectious Vaccines Revenue by Type (2020-2031)

4.2.1 Global Infectious Vaccines Revenue by Type (2020-2025)

4.2.2 Global Infectious Vaccines Revenue by Type (2026-2031)

4.2.3 Global Infectious Vaccines Revenue Market Share by Type (2020-2031)

4.3 Global Infectious Vaccines Price by Type (2020-2031)

5 Segment by Application

5.1 Global Infectious Vaccines Sales by Application (2020-2031)

5.1.1 Global Infectious Vaccines Sales by Application (2020-2025)

5.1.2 Global Infectious Vaccines Sales by Application (2026-2031)

5.1.3 Global Infectious Vaccines Sales Market Share by Application (2020-2031)

5.2 Global Infectious Vaccines Revenue by Application (2020-2031)

5.2.1 Global Infectious Vaccines Revenue by Application (2020-2025)

5.2.2 Global Infectious Vaccines Revenue by Application (2026-2031)

5.2.3 Global Infectious Vaccines Revenue Market Share by Application (2020-2031)

5.3 Global Infectious Vaccines Price by Application (2020-2031)

6 Key Companies Profiled

6.1 CSL Limited (Australia)

6.1.1 CSL Limited (Australia) Company Information

6.1.2 CSL Limited (Australia) Description and Business Overview

6.1.3 CSL Limited (Australia) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.1.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio

6.1.5 CSL Limited (Australia) Recent Developments/Updates

6.2 Bavarian Nordic (Denmark)

6.2.1 Bavarian Nordic (Denmark) Company Information

6.2.2 Bavarian Nordic (Denmark) Description and Business Overview

6.2.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio

6.2.5 Bavarian Nordic (Denmark) Recent Developments/Updates

6.3 GlaxoSmithKline plc. (U.K.)

6.3.1 GlaxoSmithKline plc. (U.K.) Company Information

6.3.2 GlaxoSmithKline plc. (U.K.) Description and Business Overview

6.3.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.3.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio

6.3.5 GlaxoSmithKline plc. (U.K.) Recent Developments/Updates

6.4 Emergent Bio Solutions Inc. (U.S.)

6.4.1 Emergent Bio Solutions Inc. (U.S.) Company Information

6.4.2 Emergent Bio Solutions Inc. (U.S.) Description and Business Overview

6.4.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio

6.4.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates

6.5 MedImmune LLC (U.S.)

6.5.1 MedImmune LLC (U.S.) Company Information

6.5.2 MedImmune LLC (U.S.) Description and Business Overview

6.5.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.5.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio

6.5.5 MedImmune LLC (U.S.) Recent Developments/Updates

6.6 Johnson and Johnson (U.S.)

6.6.1 Johnson and Johnson (U.S.) Company Information

6.6.2 Johnson and Johnson (U.S.) Description and Business Overview

6.6.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio

6.6.5 Johnson and Johnson (U.S.) Recent Developments/Updates

6.7 Novartis AG (Switzerland)

6.7.1 Novartis AG (Switzerland) Company Information

6.7.2 Novartis AG (Switzerland) Description and Business Overview

6.7.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio

6.7.5 Novartis AG (Switzerland) Recent Developments/Updates

6.8 Merck and Company (U.S.)

6.8.1 Merck and Company (U.S.) Company Information

6.8.2 Merck and Company (U.S.) Description and Business Overview

6.8.3 Merck and Company (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio

6.8.5 Merck and Company (U.S.) Recent Developments/Updates

6.9 Sanofi Pasteur (France)

6.9.1 Sanofi Pasteur (France) Company Information

6.9.2 Sanofi Pasteur (France) Description and Business Overview

6.9.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio

6.9.5 Sanofi Pasteur (France) Recent Developments/Updates

6.10 Pfizer Inc. (U.S.)

6.10.1 Pfizer Inc. (U.S.) Company Information

6.10.2 Pfizer Inc. (U.S.) Description and Business Overview

6.10.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio

6.10.5 Pfizer Inc. (U.S.) Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Infectious Vaccines Industry Chain Analysis

7.2 Infectious Vaccines Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Infectious Vaccines Production Mode & Process Analysis

7.4 Infectious Vaccines Sales and Marketing

7.4.1 Infectious Vaccines Sales Channels

7.4.2 Infectious Vaccines Distributors

7.5 Infectious Vaccines Customer Analysis

8 Infectious Vaccines Market Dynamics

8.1 Infectious Vaccines Industry Trends

8.2 Infectious Vaccines Market Drivers

8.3 Infectious Vaccines Market Challenges

8.4 Infectious Vaccines Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

CSL Limited (Australia)

Bavarian Nordic (Denmark)

GlaxoSmithKline plc. (U.K.)

Emergent Bio Solutions Inc. (U.S.)

MedImmune LLC (U.S.)

Johnson and Johnson (U.S.)

Novartis AG (Switzerland)

Merck and Company (U.S.)

Sanofi Pasteur (France)

Pfizer Inc (U.S.)

List of Tables

Table 1. Global Infectious Vaccines Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Infectious Vaccines Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Infectious Vaccines Market Competitive Situation by Manufacturers in 2024

Table 4. Global Infectious Vaccines Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Infectious Vaccines Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Infectious Vaccines Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Infectious Vaccines Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Infectious Vaccines Average Price (USD/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Infectious Vaccines, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Infectious Vaccines, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Infectious Vaccines, Product Type & Application

Table 12. Global Key Manufacturers of Infectious Vaccines, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Infectious Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Infectious Vaccines as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Infectious Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Infectious Vaccines Sales by Region (2020-2025) & (K Units)

Table 18. Global Infectious Vaccines Sales Market Share by Region (2020-2025)

Table 19. Global Infectious Vaccines Sales by Region (2026-2031) & (K Units)

Table 20. Global Infectious Vaccines Sales Market Share by Region (2026-2031)

Table 21. Global Infectious Vaccines Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Infectious Vaccines Revenue Market Share by Region (2020-2025)

Table 23. Global Infectious Vaccines Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Infectious Vaccines Revenue Market Share by Region (2026-2031)

Table 25. North America Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Infectious Vaccines Sales by Country (2020-2025) & (K Units)

Table 27. North America Infectious Vaccines Sales by Country (2026-2031) & (K Units)

Table 28. North America Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Infectious Vaccines Sales by Country (2020-2025) & (K Units)

Table 32. Europe Infectious Vaccines Sales by Country (2026-2031) & (K Units)

Table 33. Europe Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Infectious Vaccines Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Infectious Vaccines Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Infectious Vaccines Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Infectious Vaccines Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Infectious Vaccines Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Infectious Vaccines Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Infectious Vaccines Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Infectious Vaccines Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Infectious Vaccines Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Infectious Vaccines Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Infectious Vaccines Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Infectious Vaccines Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Infectious Vaccines Sales (K Units) by Type (2020-2025)

Table 51. Global Infectious Vaccines Sales (K Units) by Type (2026-2031)

Table 52. Global Infectious Vaccines Sales Market Share by Type (2020-2025)

Table 53. Global Infectious Vaccines Sales Market Share by Type (2026-2031)

Table 54. Global Infectious Vaccines Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Infectious Vaccines Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Infectious Vaccines Revenue Market Share by Type (2020-2025)

Table 57. Global Infectious Vaccines Revenue Market Share by Type (2026-2031)

Table 58. Global Infectious Vaccines Price (USD/Unit) by Type (2020-2025)

Table 59. Global Infectious Vaccines Price (USD/Unit) by Type (2026-2031)

Table 60. Global Infectious Vaccines Sales (K Units) by Application (2020-2025)

Table 61. Global Infectious Vaccines Sales (K Units) by Application (2026-2031)

Table 62. Global Infectious Vaccines Sales Market Share by Application (2020-2025)

Table 63. Global Infectious Vaccines Sales Market Share by Application (2026-2031)

Table 64. Global Infectious Vaccines Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Infectious Vaccines Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Infectious Vaccines Revenue Market Share by Application (2020-2025)

Table 67. Global Infectious Vaccines Revenue Market Share by Application (2026-2031)

Table 68. Global Infectious Vaccines Price (USD/Unit) by Application (2020-2025)

Table 69. Global Infectious Vaccines Price (USD/Unit) by Application (2026-2031)

Table 70. CSL Limited (Australia) Company Information

Table 71. CSL Limited (Australia) Description and Business Overview

Table 72. CSL Limited (Australia) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 73. CSL Limited (Australia) Infectious Vaccines Product

Table 74. CSL Limited (Australia) Recent Developments/Updates

Table 75. Bavarian Nordic (Denmark) Company Information

Table 76. Bavarian Nordic (Denmark) Description and Business Overview

Table 77. Bavarian Nordic (Denmark) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 78. Bavarian Nordic (Denmark) Infectious Vaccines Product

Table 79. Bavarian Nordic (Denmark) Recent Developments/Updates

Table 80. GlaxoSmithKline plc. (U.K.) Company Information

Table 81. GlaxoSmithKline plc. (U.K.) Description and Business Overview

Table 82. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 83. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product

Table 84. GlaxoSmithKline plc. (U.K.) Recent Developments/Updates

Table 85. Emergent Bio Solutions Inc. (U.S.) Company Information

Table 86. Emergent Bio Solutions Inc. (U.S.) Description and Business Overview

Table 87. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 88. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product

Table 89. Emergent Bio Solutions Inc. (U.S.) Recent Developments/Updates

Table 90. MedImmune LLC (U.S.) Company Information

Table 91. MedImmune LLC (U.S.) Description and Business Overview

Table 92. MedImmune LLC (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 93. MedImmune LLC (U.S.) Infectious Vaccines Product

Table 94. MedImmune LLC (U.S.) Recent Developments/Updates

Table 95. Johnson and Johnson (U.S.) Company Information

Table 96. Johnson and Johnson (U.S.) Description and Business Overview

Table 97. Johnson and Johnson (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 98. Johnson and Johnson (U.S.) Infectious Vaccines Product

Table 99. Johnson and Johnson (U.S.) Recent Developments/Updates

Table 100. Novartis AG (Switzerland) Company Information

Table 101. Novartis AG (Switzerland) Description and Business Overview

Table 102. Novartis AG (Switzerland) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 103. Novartis AG (Switzerland) Infectious Vaccines Product

Table 104. Novartis AG (Switzerland) Recent Developments/Updates

Table 105. Merck and Company (U.S.) Company Information

Table 106. Merck and Company (U.S.) Description and Business Overview

Table 107. Merck and Company (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 108. Merck and Company (U.S.) Infectious Vaccines Product

Table 109. Merck and Company (U.S.) Recent Developments/Updates

Table 110. Sanofi Pasteur (France) Company Information

Table 111. Sanofi Pasteur (France) Description and Business Overview

Table 112. Sanofi Pasteur (France) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 113. Sanofi Pasteur (France) Infectious Vaccines Product

Table 114. Sanofi Pasteur (France) Recent Developments/Updates

Table 115. Pfizer Inc. (U.S.) Company Information

Table 116. Pfizer Inc. (U.S.) Description and Business Overview

Table 117. Pfizer Inc. (U.S.) Infectious Vaccines Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 118. Pfizer Inc. (U.S.) Infectious Vaccines Product

Table 119. Pfizer Inc. (U.S.) Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Infectious Vaccines Distributors List

Table 123. Infectious Vaccines Customers List

Table 124. Infectious Vaccines Market Trends

Table 125. Infectious Vaccines Market Drivers

Table 126. Infectious Vaccines Market Challenges

Table 127. Infectious Vaccines Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

Table 131. Authors List of This Report

List of Figures

Figure 1. Product Picture of Infectious Vaccines

Figure 2. Global Infectious Vaccines Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Infectious Vaccines Market Share by Type: 2024 & 2031

Figure 4. Preventive Vaccine Product Picture

Figure 5. Therapeutic Vaccine Product Picture

Figure 6. Global Infectious Vaccines Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Infectious Vaccines Market Share by Application: 2024 & 2031

Figure 8. Adults

Figure 9. Pediatrics

Figure 10. Global Infectious Vaccines Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Infectious Vaccines Market Size (2020-2031) & (US$ Million)

Figure 12. Global Infectious Vaccines Sales (2020-2031) & (K Units)

Figure 13. Global Infectious Vaccines Average Price (USD/Unit) & (2020-2031)

Figure 14. Infectious Vaccines Report Years Considered

Figure 15. Infectious Vaccines Sales Share by Manufacturers in 2024

Figure 16. Global Infectious Vaccines Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Infectious Vaccines Players: Market Share by Revenue in Infectious Vaccines in 2024

Figure 18. Infectious Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Infectious Vaccines Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Infectious Vaccines Sales Market Share by Country (2020-2031)

Figure 21. North America Infectious Vaccines Revenue Market Share by Country (2020-2031)

Figure 22. U.S. Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Infectious Vaccines Sales Market Share by Country (2020-2031)

Figure 25. Europe Infectious Vaccines Revenue Market Share by Country (2020-2031)

Figure 26. Germany Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Infectious Vaccines Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Infectious Vaccines Revenue Market Share by Region (2020-2031)

Figure 33. China Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Taiwan Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Indonesia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Thailand Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Malaysia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Philippines Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Infectious Vaccines Sales Market Share by Country (2020-2031)

Figure 44. Latin America Infectious Vaccines Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Infectious Vaccines Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Infectious Vaccines Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. U.A.E Infectious Vaccines Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Infectious Vaccines by Type (2020-2031)

Figure 54. Global Revenue Market Share of Infectious Vaccines by Type (2020-2031)

Figure 55. Global Infectious Vaccines Price (USD/Unit) by Type (2020-2031)

Figure 56. Global Sales Market Share of Infectious Vaccines by Application (2020-2031)

Figure 57. Global Revenue Market Share of Infectious Vaccines by Application (2020-2031)

Figure 58. Global Infectious Vaccines Price (USD/Unit) by Application (2020-2031)

Figure 59. Infectious Vaccines Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions